Overview
Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions
Status:
Completed
Completed
Trial end date:
2007-03-01
2007-03-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study was undertaken to investigate the scar-improvement efficacy and safety of a single dose of avotermin (Juvista) injection into skin incisions.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
RenovoTreatments:
Mitogens
Criteria
Inclusion Criteria:- Males and females aged 18-85 years who had given written informed consent.
- Subjects with a body mass index within 15 to 35 kg/m2.
- Subjects with clinically acceptable results for the laboratory tests
- Female subjects of child bearing potential who are using acceptable method(s) of
contraception.
Exclusion Criteria:
- Subjects with history or evidence of hypertrophic or keloid scarring.
- Subjects with tattoos or previous scars within 3cm of the area to be incised.
- Subjects with prior surgery in the area to be incised within one year of the first
dosing day.
- Subjects with a history of a bleeding disorder; receiving anti-coagulant or
anti-platelet therapy.
- Subjects with evidence of any past or present clinically significant disease that may
affect the endpoints of the trial.
- Subjects with a clinically significant skin disorder that is chronic or currently
active.
- Subjects with any clinically significant medical condition or history that would
impair wound healing.
- Subjects with a history of drug hypersensitivity to any of the drugs or dressings used
in this trial.
- Subjects who are taking, or have taken any investigational product or participated in
a clinical trial in the three months prior to first trial dose administration.
- Subjects who are taking regular, continuous, oral corticosteroid therapy.
- Subjects undergoing investigations or changes in management for an existing medical
condition.
- Subjects with a history of drug abuse, or with a positive drugs of abuse test for
cocaine, amphetamines, metamphetamines, opiates or benzodiazepines during the
screening period.
- Subjects who are considered unlikely to complete the trial for whatever reason.
- Subjects with a clinically significant neurological impairment or disease.
- Subjects with any active infection.
- Subjects who are pregnant or lactating.